Ủy ban WHO về tiêu chuẩn hóa chất lượng chế phẩm sinh học nằm trong bộ Technical Report Series no 999. Xem thêm các tài liệu khác trên kênh của Công ty Cổ phần Tư vấn Thiết kế GMP EU.
Care start access bio antigen test covid 19 biotechh commerceHafsaWadood1
The care start covid-19 antigen test is a lateral flow immuno-chromatographic assay, for the qualitative detect of the SARS coronavirus nucleo-capsid protein (major antigen). It is a rapid, easy, diagnostic test for the qualitative detection of Covid-19 antigen. This device is intended for use at Point of Care (POC) testing services.
Learn how Quality By Design (QBD) principles can be applied to understand the critical processing and feed parameters affecting virus retention, allowing the development of a streamlined validation approach and robust process control strategy for virus clearance via filtration.
In this webinar, you will learn:
•How to simplify validation study design
•Identify critical process and feed parameters affecting virus retention
•How to compile a robust regulatory filing package
Abstract:
ICH Q8 defines Quality by Design (QbD) as “…a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on quality risk management.” Within the context of virus clearance for bioprocesses, QbD principles can be applied to understand the critical processing and feed parameters affecting virus retention, guiding the development of a streamlined validation approach and robust process control strategy for virus clearance unit operations. We will explore how QbD principles can be applied to downstream virus filtration of mAbs and recombinants, the application of these principles within the framework of the Viresolve® Pro Device (parvovirus retentive filter), the benefits through simplifying the validation strategy and increasing the robustness of your regulatory filing package.
Ủy ban WHO về tiêu chuẩn hóa chất lượng chế phẩm sinh học nằm trong bộ Technical Report Series no 999. Xem thêm các tài liệu khác trên kênh của Công ty Cổ phần Tư vấn Thiết kế GMP EU.
Care start access bio antigen test covid 19 biotechh commerceHafsaWadood1
The care start covid-19 antigen test is a lateral flow immuno-chromatographic assay, for the qualitative detect of the SARS coronavirus nucleo-capsid protein (major antigen). It is a rapid, easy, diagnostic test for the qualitative detection of Covid-19 antigen. This device is intended for use at Point of Care (POC) testing services.
Learn how Quality By Design (QBD) principles can be applied to understand the critical processing and feed parameters affecting virus retention, allowing the development of a streamlined validation approach and robust process control strategy for virus clearance via filtration.
In this webinar, you will learn:
•How to simplify validation study design
•Identify critical process and feed parameters affecting virus retention
•How to compile a robust regulatory filing package
Abstract:
ICH Q8 defines Quality by Design (QbD) as “…a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on quality risk management.” Within the context of virus clearance for bioprocesses, QbD principles can be applied to understand the critical processing and feed parameters affecting virus retention, guiding the development of a streamlined validation approach and robust process control strategy for virus clearance unit operations. We will explore how QbD principles can be applied to downstream virus filtration of mAbs and recombinants, the application of these principles within the framework of the Viresolve® Pro Device (parvovirus retentive filter), the benefits through simplifying the validation strategy and increasing the robustness of your regulatory filing package.
Latest Updates in Biosafety Testing for Gene TherapyMilliporeSigma
The field of Gene Therapy is moving at a fast pace providing promise of lifesaving medicines to previously unmet clinical needs. Of significant importance in the development of these novel therapies is the ability to demonstrate their safety including freedom from adventitious agents originating from raw materials or introduced during the manufacturing process.
It can be challenging, in such a fast moving field, to identify and navigate the relevant regulatory requirements and expectations for biosafety testing of such therapies. So too it can be difficult to select the optimal test methods in light of limited product availability and shelf life. Encompassing current biosafety testing approaches for bacteria, fungi, mycoplasma and viruses on starting materials to drug product, this webinar will provide you with the fundamentals to design your own Gene Therapy testing strategy.
In this webinar, you will learn:
• The most up to date regulatory expectations for Gene Therapies
• How to design a testing strategy to meet US FDA and EMA requirements
• How selecting the right biosafety test can overcome some of the unique challenges with Gene Therapies
Accelerating COVID-19 Therapies: How a streamlined biosafety strategy can get...Merck Life Sciences
Access the interactive recording: https://bit.ly/2xB2eRs
Abstract:
Vaccine and other biologic developers have long relied on traditional, growth-based methods for the detection of adventitious agents in a biosafety testing package. However, at a time where speed is of the essence, relying on testing methods that take many weeks is a real concern. Fortunately, alternative rapid detection methods can shorten timelines significantly — especially for Phase I testing. Here we will take you through these rapid alternatives and outline a testing strategy that can bring your therapy to the clinic faster.
Turning up the Compen-DIAL: Rapid Test Methods for Cell & Gene TherapiesMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3aeCPNB
Find out how we turn up the dial on quality control testing for cell and gene therapies through rapid methods for sterility, mycoplasma, and replication competent virus. We will review the current regulatory expectations as well as the benefits and limitations that come with each method.
Two of the biggest challenges with applying traditional quality control (QC) test methods to cell and gene therapies, is time to results, due to short shelf-life, and availability of sufficient sample, due to small production volumes.
So how can these challenges be overcome while still meeting regulatory expectations?
In this webinar we will discuss and review suitable methods for rapid testing of short-life cell and gene therapies that may also help conserve limited production material. We will look at benefits, limitations, and regulatory expectations for various QC needs including current and future rapid methods for sterility, mycoplasma and replication competent virus.
In this webinar, you will learn:
• Why the shelf life of a cell or gene therapy product may impact your QC testing strategy
• Current regulatory expectations surrounding rapid methods for sterility, mycoplasma and replication competent virus
• Potential impacts of pursuing a non-optimal QC testing strategy
Accuracy report of Healgen IgG/IgM Rapid Test kits AntibodyHK HuZef
1. Accuracy
1.1 Purpose
To evaluate the equivalence of COVID-19 IgG/IgM Rapid Test result and clinical diagnosis.
1.2 Method
By testing clinical samples with known results, to evaluate the accuracy of COVID-19 IgG/IgM
Rapid Test (Whole blood/Serum/Plasma).
1.3 Material
COVID-19 IgG/IgM Rapid Test Cassette (Whole blood/Serum/Plasma)
Cassette Lot1: 2002155,Lot2:2002156,Lot3:2002157
Clinical samples
1.4 Test Procedure
1) Prepare specimens: tests were taken to clinical partner to evaluate, totally 113 specimens.
2) Perform the test according to the test procedure in the package insert
1.5 Result
1) IgM
HandleCFUS Series1000and all human blood products as though capable of transmitting infectious agents. -This product has not been FDA cleared or approved; -This product has been authorized by FDA under a EUA for use by laboratories certified under CLIA, that meet requirements to perform moderate or high complexity tests; -This product is only authorized for the duration of the declaration that circumstances
exist just if ying the authorization of emergency use of in vitro diagnostics for the detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1) unless the authorization is terminated or revoked sooner.
Process development considerations for quality and safety of vaccinesDr. Priyabrata Pattnaik
"New Technologies Symposium" presentation at Annual General Meeting of Developing Country Vaccine Manufacturers Network (DCVMN), 5th-7th October 2015, Bangkok, Thailand.
detect and identify common human bacterial pathogens in high purity water.Saad Farooqi
A rapid culture independent methodology toquantitatively detect and identify common human bacterial pathogens associated with contaminated high purity water
Male urogenital tract infection is one of the most important
causes of male infertility, worldwide since genital tract
infection and inflammation have been associated with 8-35%
of male infertility cases. Bacteriospermia is defined as the
presence of bacteria in seminal fluid samples.
Bacteriospermia may play a major role in infertility. Male
accessory sex glands infection is a major risk factor in
infertility. The significance of pathophysiology of
bacteriospermia has been seriously discussed in recent years.The isolation of microorganisms from seminal fluid especially of infertile men had been widely reported. It is always recommended that microbiological study of semen can be performed in asymptomatic infertile men with leukocyto-spermia. Aerobic and anaerobic culture of semen can detect a wide range of urogenital pathogens.
Remdesivir in the Management of COVID-19: Evidence Based Approachfarah al souheil
the presentation starts with a quick overview of COVID-19 followed by Remdesivir focused clinical trials assessment and evaluation for the treatment of Corona virus
The current pandemic has generated the search for new reliable and economic alternatives for the detection of SARS-CoV-2, which produces the COVID-19 disease, one of the recommendations by the World Health Organization, is the detection of the virus by RT-qPCR methods from upper respiratory tract samples. The discomfort of the pharyngeal nasopharyngeal swab described by patients, the requirement of trained personnel, and the generation of aerosols, are factors that increase the risk of infections in this type of intake. It is known that the main means of transmission of SARS-CoV-2 is through aerosols or small droplets, which is why saliva is important as a relevant means of detecting COVID-19. In this study, a modified method based on SARS-CoV-2 RNA release from saliva is described, avoiding the isolation and purification of the genetic material and its quantification of viral copies; the results are compared with paired pharyngeal/nasopharyngeal swab samples (EF/EN). Results showed good agreement in saliva samples compared to EF/EN samples. On average, a sensitivity for virus detection of 80% was demonstrated in saliva samples competing with EF/EN samples. The use of saliva is a reliable alternative for the detection of SARS-CoV-2 by means of RT-PCR in the first days of infection, having important advantages over the conventional method. Saliva still needs to be studied completely to evaluate the detection capacity of the SARS-CoV-2 nucleic acid, however, the described process is viable, due to the decrease in materials and supplies, process times, the increment in the sampling and improvement of laboratory performance.
Latest Updates in Biosafety Testing for Gene TherapyMilliporeSigma
The field of Gene Therapy is moving at a fast pace providing promise of lifesaving medicines to previously unmet clinical needs. Of significant importance in the development of these novel therapies is the ability to demonstrate their safety including freedom from adventitious agents originating from raw materials or introduced during the manufacturing process.
It can be challenging, in such a fast moving field, to identify and navigate the relevant regulatory requirements and expectations for biosafety testing of such therapies. So too it can be difficult to select the optimal test methods in light of limited product availability and shelf life. Encompassing current biosafety testing approaches for bacteria, fungi, mycoplasma and viruses on starting materials to drug product, this webinar will provide you with the fundamentals to design your own Gene Therapy testing strategy.
In this webinar, you will learn:
• The most up to date regulatory expectations for Gene Therapies
• How to design a testing strategy to meet US FDA and EMA requirements
• How selecting the right biosafety test can overcome some of the unique challenges with Gene Therapies
Accelerating COVID-19 Therapies: How a streamlined biosafety strategy can get...Merck Life Sciences
Access the interactive recording: https://bit.ly/2xB2eRs
Abstract:
Vaccine and other biologic developers have long relied on traditional, growth-based methods for the detection of adventitious agents in a biosafety testing package. However, at a time where speed is of the essence, relying on testing methods that take many weeks is a real concern. Fortunately, alternative rapid detection methods can shorten timelines significantly — especially for Phase I testing. Here we will take you through these rapid alternatives and outline a testing strategy that can bring your therapy to the clinic faster.
Turning up the Compen-DIAL: Rapid Test Methods for Cell & Gene TherapiesMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3aeCPNB
Find out how we turn up the dial on quality control testing for cell and gene therapies through rapid methods for sterility, mycoplasma, and replication competent virus. We will review the current regulatory expectations as well as the benefits and limitations that come with each method.
Two of the biggest challenges with applying traditional quality control (QC) test methods to cell and gene therapies, is time to results, due to short shelf-life, and availability of sufficient sample, due to small production volumes.
So how can these challenges be overcome while still meeting regulatory expectations?
In this webinar we will discuss and review suitable methods for rapid testing of short-life cell and gene therapies that may also help conserve limited production material. We will look at benefits, limitations, and regulatory expectations for various QC needs including current and future rapid methods for sterility, mycoplasma and replication competent virus.
In this webinar, you will learn:
• Why the shelf life of a cell or gene therapy product may impact your QC testing strategy
• Current regulatory expectations surrounding rapid methods for sterility, mycoplasma and replication competent virus
• Potential impacts of pursuing a non-optimal QC testing strategy
Accuracy report of Healgen IgG/IgM Rapid Test kits AntibodyHK HuZef
1. Accuracy
1.1 Purpose
To evaluate the equivalence of COVID-19 IgG/IgM Rapid Test result and clinical diagnosis.
1.2 Method
By testing clinical samples with known results, to evaluate the accuracy of COVID-19 IgG/IgM
Rapid Test (Whole blood/Serum/Plasma).
1.3 Material
COVID-19 IgG/IgM Rapid Test Cassette (Whole blood/Serum/Plasma)
Cassette Lot1: 2002155,Lot2:2002156,Lot3:2002157
Clinical samples
1.4 Test Procedure
1) Prepare specimens: tests were taken to clinical partner to evaluate, totally 113 specimens.
2) Perform the test according to the test procedure in the package insert
1.5 Result
1) IgM
HandleCFUS Series1000and all human blood products as though capable of transmitting infectious agents. -This product has not been FDA cleared or approved; -This product has been authorized by FDA under a EUA for use by laboratories certified under CLIA, that meet requirements to perform moderate or high complexity tests; -This product is only authorized for the duration of the declaration that circumstances
exist just if ying the authorization of emergency use of in vitro diagnostics for the detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1) unless the authorization is terminated or revoked sooner.
Process development considerations for quality and safety of vaccinesDr. Priyabrata Pattnaik
"New Technologies Symposium" presentation at Annual General Meeting of Developing Country Vaccine Manufacturers Network (DCVMN), 5th-7th October 2015, Bangkok, Thailand.
detect and identify common human bacterial pathogens in high purity water.Saad Farooqi
A rapid culture independent methodology toquantitatively detect and identify common human bacterial pathogens associated with contaminated high purity water
Male urogenital tract infection is one of the most important
causes of male infertility, worldwide since genital tract
infection and inflammation have been associated with 8-35%
of male infertility cases. Bacteriospermia is defined as the
presence of bacteria in seminal fluid samples.
Bacteriospermia may play a major role in infertility. Male
accessory sex glands infection is a major risk factor in
infertility. The significance of pathophysiology of
bacteriospermia has been seriously discussed in recent years.The isolation of microorganisms from seminal fluid especially of infertile men had been widely reported. It is always recommended that microbiological study of semen can be performed in asymptomatic infertile men with leukocyto-spermia. Aerobic and anaerobic culture of semen can detect a wide range of urogenital pathogens.
Remdesivir in the Management of COVID-19: Evidence Based Approachfarah al souheil
the presentation starts with a quick overview of COVID-19 followed by Remdesivir focused clinical trials assessment and evaluation for the treatment of Corona virus
The current pandemic has generated the search for new reliable and economic alternatives for the detection of SARS-CoV-2, which produces the COVID-19 disease, one of the recommendations by the World Health Organization, is the detection of the virus by RT-qPCR methods from upper respiratory tract samples. The discomfort of the pharyngeal nasopharyngeal swab described by patients, the requirement of trained personnel, and the generation of aerosols, are factors that increase the risk of infections in this type of intake. It is known that the main means of transmission of SARS-CoV-2 is through aerosols or small droplets, which is why saliva is important as a relevant means of detecting COVID-19. In this study, a modified method based on SARS-CoV-2 RNA release from saliva is described, avoiding the isolation and purification of the genetic material and its quantification of viral copies; the results are compared with paired pharyngeal/nasopharyngeal swab samples (EF/EN). Results showed good agreement in saliva samples compared to EF/EN samples. On average, a sensitivity for virus detection of 80% was demonstrated in saliva samples competing with EF/EN samples. The use of saliva is a reliable alternative for the detection of SARS-CoV-2 by means of RT-PCR in the first days of infection, having important advantages over the conventional method. Saliva still needs to be studied completely to evaluate the detection capacity of the SARS-CoV-2 nucleic acid, however, the described process is viable, due to the decrease in materials and supplies, process times, the increment in the sampling and improvement of laboratory performance.
Turning up the Compen-DIAL: Rapid Test Methods for Cell & Gene TherapiesMilliporeSigma
Watch the presentation of this webinar here: https://bit.ly/3aeCPNB
Find out how we turn up the dial on quality control testing for cell and gene therapies through rapid methods for sterility, mycoplasma, and replication competent virus. We will review the current regulatory expectations as well as the benefits and limitations that come with each method.
Two of the biggest challenges with applying traditional quality control (QC) test methods to cell and gene therapies, is time to results, due to short shelf-life, and availability of sufficient sample, due to small production volumes.
So how can these challenges be overcome while still meeting regulatory expectations?
In this webinar we will discuss and review suitable methods for rapid testing of short-life cell and gene therapies that may also help conserve limited production material. We will look at benefits, limitations, and regulatory expectations for various QC needs including current and future rapid methods for sterility, mycoplasma and replication competent virus.
In this webinar, you will learn:
• Why the shelf life of a cell or gene therapy product may impact your QC testing strategy
• Current regulatory expectations surrounding rapid methods for sterility, mycoplasma and replication competent virus
• Potential impacts of pursuing a non-optimal QC testing strategy
How does the ICH Q5A revision impact viral safety strategies for biologics?MilliporeSigma
Watch the presentation of this webinar here: https://bit.ly/3t7X9tg
How does the ICH Q5A revision impact viral safety strategies for biologics?
Biologics continue to grow at a fast pace. Manufactured using cell lines of human or animal origin, these are at risk of viral contamination making safety strategies critical. A comprehensive risk mitigation strategy using multiple orthogonal measures is a regulatory expectation. ICH Q5A, the globally-harmonized guideline outlines the expectations. ICH Q5A is currently being revised to address recent scientific advancements including novel therapeutic modalities, new manufacturing paradigms, updates in viral clearance applications, and alternate detection technologies. We’ll discuss the expected changes and potential impact on viral safety strategies with case studies and examples.
In this webinar, you will learn about:
• The Importance of virus testing in biologics products
• Regulatory landscape, expectations for the Q5A revision
• What's new and changing
• Examples of alternate testing schedules, impact on viral clearance
Presented by:
Manjula Aysola, Senior Regulatory Consultant
Alison Armstrong, PhD, Sr. Director, Technical and Scientific Solutions
Viral safety of biologics: What's changing with the ICH Q5A revision?Merck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/3t7X9tg
How does the ICH Q5A revision impact viral safety strategies for biologics?
Biologics continue to grow at a fast pace. Manufactured using cell lines of human or animal origin, these are at risk of viral contamination making safety strategies critical. A comprehensive risk mitigation strategy using multiple orthogonal measures is a regulatory expectation. ICH Q5A, the globally-harmonized guideline outlines the expectations. ICH Q5A is currently being revised to address recent scientific advancements including novel therapeutic modalities, new manufacturing paradigms, updates in viral clearance applications, and alternate detection technologies. We’ll discuss the expected changes and potential impact on viral safety strategies with case studies and examples.
In this webinar, you will learn about:
• The Importance of virus testing in biologics products
• Regulatory landscape, expectations for the Q5A revision
• What's new and changing
• Examples of alternate testing schedules, impact on viral clearance
Presented by:
Manjula Aysola, Senior Regulatory Consultant
Alison Armstrong, PhD, Sr. Director, Technical and Scientific Solutions
GLP is an FDA regulation.
It is defined in OECD principles as ―a quality system concerned with organizational process and the conditions under which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, archived and reported.
GLP extends to include food and color additives, animal food additives, human and animal drugs, medical devices for human use, biological products, and electronic products.
GLP is a formal regulation that was created by the USFDA in 1978 having worldwide impact.
Non-US companies that wanted to do business with the United states or register their pharmacies in the United States had to comply with the United States GLP regulations.
In 1981 an organization named OECD (organization for economic co-operation and development ) produced GLP principles that are international standard.
Quality and Integrity of the Safety Data
In the early 70’s FDA became aware of cases of ( PLP ) poor laboratory practice all over the United States.
FDA decided to do an in-depth investigation in 40 toxicology labs. They discovered a lot fraudulent activities and a lot of poor lab practices.
Examples of some of these ( PLP )poor lab practices found were: Equipment not been calibrated to standard form , therefore giving wrong measurements. Incorrect/inaccurate accounts of the actual lab study.
Considerations for Diagnostic COVID-19 Tests in the 4 Medical Testing Centre ...semualkaira
In this study during the coronavirus disease in 2021 (COVID-19)
pandemic, design, development, validation, verification incidence
and implementation of diagnostic tests are reported by many diagnostic tests from May until December 2021 we managed to
establish clinical validation and formal approval. In this article
we summarize the crucial role of diagnostic tests during the first
global wave of COVID-19. The technical and implementation and
diagnostics during a possible resurgence of COVID-19 in future
global waves or regional outbreaks. We continued global improvement in diagnostic test that is essential for more rapid detection of
patients, possibly at the point of care, and for optimized prevention
and treatment
Basic laboratory procedures in clinical bacteriologyamin beni
book of Basic laboratory procedures in clinical bacteriology Basic laboratory procedures in clinical bacteriology Basic laboratory procedures in clinical bacteriology Basic laboratory procedures in clinical bacteriology
A original article presentation in journal club.
It gives you better idea how to present a research article.
A cross sectional study was conducted to compare two different methods first is rapid card test and other is real time pcr for the diagnosis of corona virus disease.
This presentation explores a brief idea about the structural and functional attributes of nucleotides, the structure and function of genetic materials along with the impact of UV rays and pH upon them.
Deep Behavioral Phenotyping in Systems Neuroscience for Functional Atlasing a...Ana Luísa Pinho
Functional Magnetic Resonance Imaging (fMRI) provides means to characterize brain activations in response to behavior. However, cognitive neuroscience has been limited to group-level effects referring to the performance of specific tasks. To obtain the functional profile of elementary cognitive mechanisms, the combination of brain responses to many tasks is required. Yet, to date, both structural atlases and parcellation-based activations do not fully account for cognitive function and still present several limitations. Further, they do not adapt overall to individual characteristics. In this talk, I will give an account of deep-behavioral phenotyping strategies, namely data-driven methods in large task-fMRI datasets, to optimize functional brain-data collection and improve inference of effects-of-interest related to mental processes. Key to this approach is the employment of fast multi-functional paradigms rich on features that can be well parametrized and, consequently, facilitate the creation of psycho-physiological constructs to be modelled with imaging data. Particular emphasis will be given to music stimuli when studying high-order cognitive mechanisms, due to their ecological nature and quality to enable complex behavior compounded by discrete entities. I will also discuss how deep-behavioral phenotyping and individualized models applied to neuroimaging data can better account for the subject-specific organization of domain-general cognitive systems in the human brain. Finally, the accumulation of functional brain signatures brings the possibility to clarify relationships among tasks and create a univocal link between brain systems and mental functions through: (1) the development of ontologies proposing an organization of cognitive processes; and (2) brain-network taxonomies describing functional specialization. To this end, tools to improve commensurability in cognitive science are necessary, such as public repositories, ontology-based platforms and automated meta-analysis tools. I will thus discuss some brain-atlasing resources currently under development, and their applicability in cognitive as well as clinical neuroscience.
Nutraceutical market, scope and growth: Herbal drug technologyLokesh Patil
As consumer awareness of health and wellness rises, the nutraceutical market—which includes goods like functional meals, drinks, and dietary supplements that provide health advantages beyond basic nutrition—is growing significantly. As healthcare expenses rise, the population ages, and people want natural and preventative health solutions more and more, this industry is increasing quickly. Further driving market expansion are product formulation innovations and the use of cutting-edge technology for customized nutrition. With its worldwide reach, the nutraceutical industry is expected to keep growing and provide significant chances for research and investment in a number of categories, including vitamins, minerals, probiotics, and herbal supplements.
Salas, V. (2024) "John of St. Thomas (Poinsot) on the Science of Sacred Theol...Studia Poinsotiana
I Introduction
II Subalternation and Theology
III Theology and Dogmatic Declarations
IV The Mixed Principles of Theology
V Virtual Revelation: The Unity of Theology
VI Theology as a Natural Science
VII Theology’s Certitude
VIII Conclusion
Notes
Bibliography
All the contents are fully attributable to the author, Doctor Victor Salas. Should you wish to get this text republished, get in touch with the author or the editorial committee of the Studia Poinsotiana. Insofar as possible, we will be happy to broker your contact.
(May 29th, 2024) Advancements in Intravital Microscopy- Insights for Preclini...Scintica Instrumentation
Intravital microscopy (IVM) is a powerful tool utilized to study cellular behavior over time and space in vivo. Much of our understanding of cell biology has been accomplished using various in vitro and ex vivo methods; however, these studies do not necessarily reflect the natural dynamics of biological processes. Unlike traditional cell culture or fixed tissue imaging, IVM allows for the ultra-fast high-resolution imaging of cellular processes over time and space and were studied in its natural environment. Real-time visualization of biological processes in the context of an intact organism helps maintain physiological relevance and provide insights into the progression of disease, response to treatments or developmental processes.
In this webinar we give an overview of advanced applications of the IVM system in preclinical research. IVIM technology is a provider of all-in-one intravital microscopy systems and solutions optimized for in vivo imaging of live animal models at sub-micron resolution. The system’s unique features and user-friendly software enables researchers to probe fast dynamic biological processes such as immune cell tracking, cell-cell interaction as well as vascularization and tumor metastasis with exceptional detail. This webinar will also give an overview of IVM being utilized in drug development, offering a view into the intricate interaction between drugs/nanoparticles and tissues in vivo and allows for the evaluation of therapeutic intervention in a variety of tissues and organs. This interdisciplinary collaboration continues to drive the advancements of novel therapeutic strategies.
What is greenhouse gasses and how many gasses are there to affect the Earth.moosaasad1975
What are greenhouse gasses how they affect the earth and its environment what is the future of the environment and earth how the weather and the climate effects.
Slide 1: Title Slide
Extrachromosomal Inheritance
Slide 2: Introduction to Extrachromosomal Inheritance
Definition: Extrachromosomal inheritance refers to the transmission of genetic material that is not found within the nucleus.
Key Components: Involves genes located in mitochondria, chloroplasts, and plasmids.
Slide 3: Mitochondrial Inheritance
Mitochondria: Organelles responsible for energy production.
Mitochondrial DNA (mtDNA): Circular DNA molecule found in mitochondria.
Inheritance Pattern: Maternally inherited, meaning it is passed from mothers to all their offspring.
Diseases: Examples include Leber’s hereditary optic neuropathy (LHON) and mitochondrial myopathy.
Slide 4: Chloroplast Inheritance
Chloroplasts: Organelles responsible for photosynthesis in plants.
Chloroplast DNA (cpDNA): Circular DNA molecule found in chloroplasts.
Inheritance Pattern: Often maternally inherited in most plants, but can vary in some species.
Examples: Variegation in plants, where leaf color patterns are determined by chloroplast DNA.
Slide 5: Plasmid Inheritance
Plasmids: Small, circular DNA molecules found in bacteria and some eukaryotes.
Features: Can carry antibiotic resistance genes and can be transferred between cells through processes like conjugation.
Significance: Important in biotechnology for gene cloning and genetic engineering.
Slide 6: Mechanisms of Extrachromosomal Inheritance
Non-Mendelian Patterns: Do not follow Mendel’s laws of inheritance.
Cytoplasmic Segregation: During cell division, organelles like mitochondria and chloroplasts are randomly distributed to daughter cells.
Heteroplasmy: Presence of more than one type of organellar genome within a cell, leading to variation in expression.
Slide 7: Examples of Extrachromosomal Inheritance
Four O’clock Plant (Mirabilis jalapa): Shows variegated leaves due to different cpDNA in leaf cells.
Petite Mutants in Yeast: Result from mutations in mitochondrial DNA affecting respiration.
Slide 8: Importance of Extrachromosomal Inheritance
Evolution: Provides insight into the evolution of eukaryotic cells.
Medicine: Understanding mitochondrial inheritance helps in diagnosing and treating mitochondrial diseases.
Agriculture: Chloroplast inheritance can be used in plant breeding and genetic modification.
Slide 9: Recent Research and Advances
Gene Editing: Techniques like CRISPR-Cas9 are being used to edit mitochondrial and chloroplast DNA.
Therapies: Development of mitochondrial replacement therapy (MRT) for preventing mitochondrial diseases.
Slide 10: Conclusion
Summary: Extrachromosomal inheritance involves the transmission of genetic material outside the nucleus and plays a crucial role in genetics, medicine, and biotechnology.
Future Directions: Continued research and technological advancements hold promise for new treatments and applications.
Slide 11: Questions and Discussion
Invite Audience: Open the floor for any questions or further discussion on the topic.
Generation of false positive sars co v-2 antigen results with testing conditions outside manufacturer recommendations
1. 1
Generation of false positive SARS-CoV-2 antigen results with testing conditions outside manufacturer
1
recommendations: A scientific approach to pandemic misinformation
2
Glenn Patriquin1,2
,Ross J. Davidson1-4
, Todd F. Hatchette1-4
, Breanne M. Head5
, Edgard Mejia5
, Michael G.
3
Becker5
, Adrienne Meyers5
, Paul Sandstrom5
, Jacob Hatchette6
, Ava Block6
, Nicole Smith6
, John Ross6
,
4
Jason J. LeBlanc1-4*
5
1
Division of Microbiology, Department of Pathology and Laboratory Medicine, Nova Scotia Health (NSH),
6
Halifax, Nova Scotia, Canada.
7
2
Department of Pathology, Dalhousie University, Halifax, Nova Scotia, Canada.
8
3
Department of Medicine (Infectious Diseases), Dalhousie University, Halifax, Nova Scotia, Canada.
9
4
Department of Microbiology and Immunology, Dalhousie University, Halifax, Nova Scotia, Canada.
10
5
National Microbiology Laboratory (NML), Public Health Agency of Canada (PHAC), Winnipeg, Manitoba,
11
Canada.
12
6
Praxes Medical Group, Halifax, Nova Scotia, Canada.
13
Key Words: COVID-19, SARS-CoV-2, antigen, false positive, Panbio
14
Abstract word count: 250
15
Body word count: 2989
16
*Corresponding author: Jason J. LeBlanc, PhD, FCCM, D(ABMM)
17
Division of Microbiology, Department of Pathology and Laboratory
18
Medicine, Nova Scotia Health (NSH),
19
Room 404B, MacKenzie Building
20
5788 University Avenue, Halifax, Nova Scotia, B3H 1V8
21
Tel.: +1 902 473 7698; Fax: +1 902 473 7971
22
Email: jason.leblanc@nshealth.ca
23
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
2. 2
Abstract
24
Objectives. Antigen-based rapid diagnostics tests (Ag-RDTs) are useful tools for SARS-CoV-2 detection.
25
However, misleading demonstrations of the Abbott Panbio COVID-19 Ag-RDT on social media claimed
26
that SARS-CoV-2 antigen could be detected in municipal water and food products. To offer a scientific
27
rebuttal to pandemic misinformation and disinformation, this study explored the impact of using the
28
Panbio SARS-CoV-2 assay with conditions falling outside of manufacturer recommendations.
29
Methods. Using Panbio, various water and food products, laboratory buffers, and SARS-CoV-2-negative
30
clinical specimens were tested, with and without manufacturer buffer. Additional experiments were
31
conducted to assess the role of each Panbio buffer component (tricine, NaCl, pH, and tween-20), as well
32
as the impact of temperatures (4°C, 20°C , and 45°C) and humidity (90%) on assay performance.
33
Results. Direct sample testing (without the kit buffer), resulted in false positive signals resembling those
34
obtained with SARS-CoV-2-positive controls tested under proper conditions. The likely explanation of
35
these artifacts is non-specific interactions between the SARS-CoV-2-specific conjugated and capture
36
antibodies, as proteinase K treatment abrogated this phenomenon, and thermal shift assays showed pH-
37
induced conformational changes under conditions promoting artifact formation. Omitting, altering, and
38
reverse engineering the kit buffer all supported the importance of maintaining buffering capacity, ionic
39
strength, and pH for accurate kit function. Interestingly, the Panbio assay could tolerate some extremes
40
of temperature and humidity outside of manufacturer claims.
41
Conclusions. Our data support strict adherence to manufacturer instructions to avoid false positive
42
SARS-CoV-2 Ag-RDT reactions, otherwise resulting in anxiety, overuse of public health resources, and
43
dissemination of misinformation.
44
45
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
3. 3
Introduction
46
High demand for diagnostic testing during the COVID-19 pandemic led to the development of various
47
technologies for SARS-CoV-2 detection.[1] Nucleic acid amplification tests (NAATs), like real-time RT-
48
PCR, are considered the reference methods [1-3], but antigen-based rapid diagnostic tests (Ag-RDTs)
49
have been widely used due to their ease-of use, rapid results, and ability to be performed outside of a
50
laboratory setting.[1] Many Ag-RDTs have been licensed as point-of-care (POC) devices for SARS-CoV-2
51
detection [4,5], but their performance can vary between methods, testing frequency, and settings in
52
which they are used.[6-12] Ag-RDTs are well recognized to be less sensitive and specific than commercial
53
NAATs, and false positive results from Ag-RDTs are known to occur, particularly in settings of low disease
54
prevalence.[13,14]
55
The intended use of the COVID-19 Ag Rapid Test Device is qualitative detection of SARS-CoV-2 antigen
56
(i.e. nucleocapsid protein) from nasal swabs (or nasopharyngeal swabs, depending on the formulation of
57
the kit). The manufacturer kit insert states that instructions must be strictly followed by a trained
58
healthcare professional to achieve accurate results, and the kit includes a buffer used for antigen
59
extraction from the swabs used for specimen collection as well as viral inactivation. However,
60
misleading demonstrations of a SARS-CoV-2 Ag-RDT (i.e. Panbio) on social media platforms have claimed
61
that SARS-CoV-2 antigen can readily be detected in municipal water and commercial food and
62
beverages, if tested directly onto the Panbio test device.[15-18] Moreover, on social media, the misuse
63
of an Ag-RDT was propagated by pupils in attempts to miss time in school.[15-18] However, in both
64
these examples, the results are erroneous as direct testing of samples onto the Ag-RDTs device is not
65
recommended by manufacturer. With misinformation and disinformation often perpetuated on social
66
media, and aberrant results obtained from improper use of the kit, unsubstantiated claims can
67
undermine confidence in SARS-CoV-2 diagnostic testing and erode trust in public health efforts. As such,
68
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
4. 4
it is important to use science-based approaches to demonstrate that while non-specific reactivity can
69
occur when testing is performed under inappropriate conditions, SARS-CoV-2 is not truly present in food
70
or potable water samples. For healthcare professionals, aberrant test results arising from procedures
71
that deviate from the kit instructions would not be surprising. When manufacturer instructions are
72
followed, the expected false positivity rate would be very low (i.e. between 0.4 and 1.2%) [6-12], and
73
the positive Ag-RDTs are often repeated using an alternative method such as a NAAT.[1-3] On the other
74
hand, the cause of false positive Ag-RDT reactions are rarely investigated.
75
This study deliberately evaluated conditions that fell outside of those recommended by the
76
manufacturer, which had the potential to generate aberrant Ag-RDT reactions, including unregulated
77
buffering capacity or ionic strength, and extremes of temperature, humidity, and pH. As expected from
78
social media claims, direct testing of a wide variety of food products and water samples generated false
79
positive results with the Panbio Ag-RDT; however, this prompted further investigations into the
80
underlying mechanism of artifact generation. Panbio kit extraction buffer was omitted, diluted, or
81
reverse engineered, to help demonstrate the importance of the buffer and each of its components.
82
Overall, by identifying conditions that could favor artifact generation, this study not only helps provide
83
evidence supporting the importance of following manufacturer instructions, but helps in the
84
understanding of possible causes of false positive reactions using Ag-RDTs, which can be informative to
85
healthcare professionals, test manufacturers, and other users of the products.
86
Materials and methods
87
Sample types
88
Ag-RDT samples included food products (Table 1), water, laboratory buffers, specimen transport media,
89
and four different clinical specimens types previously tested negative by real-time RT-PCR in routine
90
diagnostic testing: 1) 30 nasopharyngeal (NP) swabs in universal transport media (UTM); 2) 30
91
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
5. 5
oropharyngeal and bilateral nares (OP/N) swabs in phosphate buffered saline (PBS) [19,20]; 3) 30
92
bronchoalveolar lavages (BAL); and 4) 30 saline gargles (Table 1).[21]
93
Antigen and molecular testing
94
SARS-CoV-2 nucleocapsid antigen detection was performed using the Abbott Panbio COVID-19 Rapid
95
Antigen Test (Figure 1) and the BD Veritor System for Rapid Detection of SARS-CoV-2. Each kit's nasal
96
swabs were dipped into the test samples, placed in the appropriate kit buffers, and 3 or 5 drops were
97
used to inoculate the sample wells of the Veritor and Panbio cassettes, respectively, as per the
98
manufacturer recommendations. Each sample was also tested without manufacturer buffer (i.e. direct
99
sample testing), mirroring the test procedure recommended for clinical specimens. Results were
100
visualized by the unaided eye after 15 minutes, and Veritor readouts also included automated detection
101
using a BD Veritor Plus instrument. Panbio test results were based on the kit insert, in which the
102
presence of the control band alone was considered a negative results, the presence of both the control
103
and target bands was considered positive, and the presence of the target band alone or absence of
104
bands was considered invalid (Figure 1). Real-time RT-PCR testing was performed for all specimens
105
except food products using the Roche Diagnostics cobas SARS-CoV-2 Test on the cobas 6800 instrument.
106
Assessing the role of the Panbio buffer and its components
107
PCR-grade water (Invitrogen) was chosen as a representative matrix to generate false positive Panbio
108
results (Table 1). To assess the assay tolerability to buffer dilution, Panbio buffer was subjected to 2-fold
109
serial dilutions in PCR-grade water, and testing was performed at 4C, 20C, and 37C (Figure 2A). The
110
exact composition of Panbio buffer is proprietary, yet according to the product insert, it consists of
111
tricine, sodium chloride (NaCl), tween-20, proclin 300, and sodium azide (<0.1%). To assess the role of
112
these components, the buffer was reverse engineered. Solutions of tricine (1 mM to 1M), from pH 3 to
113
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
6. 6
12 were prepared (Figure 2B), with or without 1% tween-20. The contribution of ionic strength was
114
assessed using NaCl (1 mM to 1M) in 100 mM tricine solutions pH 3 to 12 (Figure 2C).
115
Effect of temperature and humidity on Panbio performance
116
According to manufacturer specifications, PanBio kits should be stored between 2 to 30 °C, and all kit
117
components brought to room temperature (15 to 30 °C) for 30 minutes prior to use. To assess the
118
impact of storage temperature, sealed PanBio test devices were incubated for one hour at 4°C, 20°C or
119
45°C (Table S1). The 45°C incubations were performed with 90% relative humidity (RH) using a Binder
120
Constant Climate Chamber (model KBF 115) (Table S1). Test devices were removed from their
121
packaging, and incubations were repeated under the same conditions. Testing was performed using 20
122
µL of gamma-irradiated SARS-CoV-2 into 280 µL of PanBio buffer. Viral stocks [at 1.2 x 106
plaque
123
forming units (PFU)/mL] were diluted in PBS (pH = 7.4) to concentrations spanning 1.2 x 105
to 1.1 x 103
124
PFU/mL (Table S1). PanBio buffer was used as negative controls. Freeze-thaw effects were investigated
125
by incubation of test components at -20°C for 16 hours before thawing and testing.
126
Investigations into possible causes of false positive results
127
Using "conjugate pad transplantation" (Figure 3A), the proprietary gold conjugated-antibodies of the
128
Panbio device (i.e. the SARS-CoV-specific human IgG and the chicken IgY used for the control) were
129
accessed from disassembled Panbio cassettes. Each conjugate pad was resuspended with 100 µl of
130
Panbio buffer, PCR-grade water, or tricine solutions, and the suspensions were subjected to various
131
treatments. Proteinase K (PK) (Qiagen GmbH., Hilden, Germany) was used at 100 µg/reaction for one
132
hour at 56C, followed by enzyme inactivation at 70C for 10 minutes (Figure 3B). Untreated and heat
133
treatment controls were included as controls (Figure 3B). The remaining conjugate-free pads are washed
134
three times with 1 ml of water or buffer, dried using a Whatman #1 filter, and re-introduced into the
135
Panbio cassettes. For testing, 25 µl of each water- or buffer-derived conjugated-antibody suspension
136
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
7. 7
was added onto the conjugate pads of reassembled cassettes, followed by addition of 5 drops into the
137
sample well of either positive or negative controls processed in water or the kit buffer.
138
In a second set of experiments (Figure 3A, dashed lines), the control chicken IgY was removed from the
139
SARS-CoV-2-specific IgG by pre-treatment of the conjugate suspensions with a fragment of the
140
nitrocellulose membrane from the Panbio test device containing the immobilized mouse monoclonal
141
anti-chicken IgY. Fragments were excised at approximately 3 mm on each side of the control line
142
indicated on the Panbio cassette. For each 100 µl of conjugate suspension, one fragment was added,
143
followed by a 15 min incubation at room temperature. Then, SARS-CoV-2-specific conjugated antibody
144
were removed and subjected to lateral flow and thermal shift assays to explore possible pH-induced
145
conformational changes (Figure 4).
146
Conjugated SARS-CoV-2 IgG thermal shift assays
147
Differential scanning fluorometry (DSF), also known as thermal shift assays, relies on monitoring
148
temperature-dependent unfolding of a protein, in presence of a fluorescent dye that is quenched in
149
water but fluoresces when bound to hydrophobic residues.[22-24] As a native protein is unfolded with
150
heat, different hydrophobic residues are exposed, and the melting temperature (Tm) can be calculated
151
for various test conditions. In this study, 25 μl reaction containing 10× SYPRO Orange (Invitrogen,
152
Eugene, Oregon, USA) was added to the gold-conjugated human IgG specific to SARS-CoV-2
153
resuspended in Panbio buffer or 100 mM of tricine at pH values consistent (i.e. pH 5-7) and inconsistent
154
(i.e. pH 8-10) with artifact formation (Figure 4A and B). A similar set of experiments with performed with
155
addition of 1% tween-20. Melting curve analysis was performed by increasing the temperature from
156
25°C to 99.9°C at a ramp rate of 1% with continuous fluorescence at 610 nm using an Applied
157
Biosystems 7500 Fast instrument. Tm values were calculated by manufacturer software (Figure 4B).
158
Results
159
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
8. 8
False positives in food, water, buffers, media, and clinical specimens
160
With the exception of soft drinks and some milk products with high fat content which produced negative
161
or weak false positive reactions, most of the food products that were tested directly onto the Panbio
162
cassette produced a strong positive SARS-CoV-2 signals that resembled those obtained with the kit
163
positive control (Table 1). It is interesting that, milk products are often used as blocking agents in
164
immunoassays to prevent non-specific binding of antibodies.[1,27] Direct testing of known highly acidic
165
samples caused invalid results for both Panbio and Veritor. All other products were Veritor-negative.
166
When nasal swabs were used to sample the various products and processing occurred with
167
manufacturer buffer, no false positives or invalid results were observed.
168
Multiple water samples were evaluated with tested pH values between 4.00 and 9.33, and differences in
169
supplier-described purification methods, and mineral and electrolyte composition (Table 1). Direct
170
testing onto Panbio test devices showed strong false positive SARS-CoV-2 signals, while samples diluted
171
in Panbio buffer did not produce any artifacts. Notably, water samples near the pH of the Panbio buffer
172
(pH 8.78) also displayed strong false positive signals, suggesting the mechanism behind artifact
173
formation is not, or not solely, pH-dependent. To investigate the possible roles of buffering capacity and
174
ionic strength, commonly used laboratory buffers and buffer-containing viral transport media spanning
175
various pH values (5.62 to 8.78) were tested (Table 1). With the exception of Tris-EDTA (TE), all other
176
buffers and media generated weakly positive or negative results (Table 1). All water samples, buffers,
177
and media were RT-PCR and Veritor-negative, suggesting absence of viral RNA and nucleocapsid antigen,
178
respectively (Table 1).
179
Given that weak false positive were results observed with UTM, PBS, and saline, direct testing was
180
performed on clinical specimens containing these media and buffers. With direct testing onto Panbio
181
cassettes, false positive results were seen in 93.3% of NP swabs in UTM, 86.7% of OP/N swabs in PBS,
182
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
9. 9
90.0% of BALs, and 90.0% of the saline gargles (Table 1). All specimens were negative when Panbio
183
buffer was used, which was consistent with the Veritor and RT-PCR results.
184
Role of the Panbio buffer and its components
185
Panbio buffer diluted in water at ratios greater than 1:8, and occasionally at 1:10, resulted in artifact
186
formation (Figure 2A). Similarly, when buffering capacity was poor or lost when using low tricine
187
concentrations (1 or 10 mM), strong false positive signals were seen across a broad range of pH values
188
(Figure 2B). In contrast, high tricine concentrations (100 mM or 1M) prevented artifact formation at pH
189
9 and above, which is consistent with the measured pH of Panbio buffer at 8.78 (Figure 2B and Table 1).
190
Similar to the buffering capacity, regulated ionic strength also played an important role, as high NaCl
191
concentrations (100 mM or 1M) reduced or prevented false positive results, whereas lower
192
concentrations (1 and 10 mM) mirrored NaCl-free conditions (Figures 2B and 2C). Invalid results
193
sometimes obtained at pH 3 and 12 (Figure 2B and 2C). Tween-20 (1%) was added to all tricine solutions,
194
but had no impact on results (data not shown). Antimicrobial agents in the Panbio buffer (i.e. proclin
195
300 and sodium azide) were not investigated due to their unlikely contribution to artifact generation.
196
Investigations into the mechanism of artifact generation
197
Following conjugate pad transplantation (Figure 3A), positive and negative control swabs displayed
198
expected results after inoculation onto re-assembled Panbio cassettes in which resuspended conjugated
199
antibodies were re-introduced. Water-resuspended conjugated antibody generated a strong false
200
positive target signal, which was eliminated following PK treatment (Figure 3B). Removal of the gold-
201
conjugated IgY antibody from the conjugate suspensions did not impair Panbio test performance, and
202
the strong false positive SARS-CoV-2 signal from water remained (Figure 3C). These findings suggest that
203
the gold-conjugated human anti-SARS-CoV-2 IgG is responsible for the non-specific interactions with the
204
immobilized anti-SARS-CoV-2 capture antibody on the test device nitrocellulose membrane. Thermal
205
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
10. 10
shift assays in 100 mM tricine solutions were used to compare structural differences of the anti-SARS-
206
CoV-2 IgG at pH values consistent (i.e. pH 5-7) or inconsistent (i.e. pH 8-10) with artifact formation
207
(Figure 4A and B). Tm values were significantly different in tricine solutions between pH 5 to 7 (at 68.4 ±
208
2.6, 71.4 ± 1.2, 72.5 ± 1.0, respectively) compared to pH 8 to 10 (at 75.6 ± 1.0, 76.8 ± 1.1 and 77.6 ± 1.4,
209
respectively) (Figure 4A and B). Tm values at pH 4 and 11 were inconsistent, while no Tm values could be
210
established at pH 3 and 12. Of note, the Panbio buffer could not be used directly for thermal shift
211
experiments, due to high background fluorescence with SYPRO orange. The cause of this background
212
fluorescence was revealed in tricine solutions containing 1% Tween-20, which demonstrated similar
213
interference.
214
Impact of heat and humidity on Panbio kit function
215
In all test conditions evaluated (Table S1), no deleterious effects on test sensitivity or specificity were
216
observed concerning temperature or humidity. In a complimentary series of experiments, Panbio buffer
217
dilutions showed similar findings, regardless of operating temperature (Figure 2A).
218
Discussion
219
False positive and negative results occur with any diagnostic test, but are increasingly likely when
220
manufacturer recommendations are not followed.[1,13,14] This study demonstrated in absence of
221
manufacturer buffer, a variety of food, water, laboratory buffer, specimen transport media, and clinical
222
specimens resulted in false positive reactions with the Panbio Ag-RDT. These data are consistent with
223
others [25] who recognized the importance of Ag-RDT kit buffers. On the other hand, false negative
224
results would typically be expected with aberrant test conditions. The generation of false positive signals
225
demonstrated in this study prompted an investigation into the underlying causes of this phenomenon.
226
Uncontrolled conditions of pH, buffering capacity, and ionic strength, all favored artifact generation,
227
whereas temperature and humidity were not contributory under the tested parameters. In review of the
228
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
11. 11
literature, possible causes of false positive Ag-RDT results include cross-reactions [26], interfering
229
substances [27], and improper operating or storage conditions for temperature or humidity.[28]. Cross-
230
reacting or interfering substances common to all samples tested in the study is unlikely. Temperature
231
extremes have been shown to induce conformational changes in SARS-CoV-2 antibodies, leading to non-
232
specific binding [29]; however, in this study, Panbio was unaffected by temperature and humidity
233
conditions evaluated. As described below, the most likely cause of Panbio false positive results was
234
aberrant protein-protein interactions faced with improper buffer conditions, ionic strength, or pH.
235
In a previous study [25], 20 of 27 of the malaria Ag-RDTs brands evaluated showed false positive
236
reactions when the manufacturer buffer was replaced with saline, tap water, or distilled water. Distilled
237
water alone generated false positive reactions [25], similar to what was observed in this study with
238
Panbio (Table 1). Possible explanations for their findings included inefficient resuspension of blocking
239
agents, altered capillary flow rates and decreased flushing of contaminating substances, and finally, non-
240
specific interactions between the conjugated and capture antibodies faced with uncontrolled buffering
241
and ionic strength conditions.[25] Tricine is a zwitterionic amino acid with a pKa of 8.26, and would be
242
negatively charged at the measured pH of 8.78 in the Panbio buffer. Therefore, under recommended
243
testing conditions, tricine may mask positively charged residues on the SARS-CoV-2-specific conjugated
244
and capture antibodies, while uncontrolled buffer conditions would favor aberrant electrostatic or
245
hydrophobic interactions between the two antibodies, resulting in false positive results. Supporting this
246
theory, PK treatment eliminated the false positive Panbio results generated by water, and the
247
propensity to generate this artifact varied with buffering capacity, pH, and ionic strength. Removal of
248
the gold-conjugated chicken IgY (used for control band detection) did not alter formation of the SARS-
249
CoV-2 target artifact formation, suggesting the conjugated SARS-CoV-2-specific IgG alone is responsible
250
for artifact formation through non-specific binding to the SARS-CoV-2-specific capture antibody
251
immobilized on the nitrocellulose membrane (Figure 1B). Finally, thermal shift assays were performed
252
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
12. 12
on the conjugated anti-SARS-CoV-2 IgG, and pH-dependent conformation changes were observed under
253
conditions causing false positive results or not (Figure 4). This study was not able to further investigate
254
pH-dependent binding interactions between the conjugated and capture anti-SARS-CoV-2 antibodies, as
255
the latter is immobilised on the nitrocellulose membrane, and not available in an unfixed formulation
256
due to the proprietary nature of the Panbio assay.
257
False positive reactions with the Panbio Ag-RDT have the potential to cause a significant impact to Public
258
Health. To date, over 200 million Panbio Ag-RDT tests have been distributed to over 120 countries
259
worldwide, for use in healthcare settings, businesses, or home self-testing. In low prevalence
260
populations, positive Ag-RDTs are typically confirmed by clinical laboratories with NAATs, thereby
261
limiting the overall public health impact of the possible artifacts described in this study.[1-3] However, in
262
programs where home self-testing kits are deployed [20,21,30], it is important to educate users on the
263
importance of strict adherence to manufacturer instructions. Another area for consideration is outdoor
264
testing strategies (e.g. drive-thru testing), where the Panbio kit supplies may be exposed to precipitation
265
and fluctuations in temperature and humidity.[30] While temperature and humidity did not alter the
266
Panbio performance in this study, rain water was shown to cause false positive reactions if processed
267
without buffer. Haage et al. [28] demonstrated that prolonged exposure to elevated temperatures
268
affected the sensitivity of SARS-CoV-2 detection by some Ag-RDTs, whereas low temperatures impaired
269
specificity of assays including Panbio.[25] However, an alternative explanation for the false positives
270
observed at low temperatures by these investigators could be the use non-validated specimen types (i.e.
271
NP swabs in PBS).[25] In this study, PBS alone caused false positive results in absence of buffer. The
272
quantity of PBS material (i.e. 20 µl in approximately 300 µl of buffer) used by Haage et al. [25] was
273
similar to the limit of tolerability of Panbio to dilution in water observed in this study of between 1:8 to
274
1:10.
275
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
13. 13
It should be noted that the findings of this study with false positives results observed with Panbio when
276
tested outside manufacturer claims should not be extrapolated to other Ag-RDTs without supporting
277
evidence, as a second SARS-CoV-2 antigen test (i.e. BD Veritor) did not show similar findings. Other Ag-
278
RDTs could rely on different assay principles, and would need to be investigated independently.
279
Overall, this manuscript provides rigorous scientific evidence that erroneous false positive SARS-CoV-2
280
results can occur with improper test conditions with the Panbio Ag-RDT, resulting in non-specific
281
interaction between the SARS-CoV-2-specific conjugated and capture antibodies. While generation of
282
false positive results from direct testing of products onto Panbio Ag-RDT devices may not surprise some
283
healthcare professionals, having a better understanding of the importance of the buffer and its
284
components, as well as knowing the mechanism of false positive generation, can help dispute unsound
285
demonstrations on social media, and help inform users on the value of following the manufacturer
286
instructions.
287
Acknowledgement
288
The authors would like to thank the Special Pathogens Program of the National Microbiology Laboratory
289
(NML) (Winnipeg, MB) for the gamma-irradiated SARS-CoV-2 virus used in this study. We would also like
290
to recognize the ongoing efforts of the all the NML and NSH staff for their dedication and exceptional
291
services throughout the pandemic, including the help with RT-PCR testing during this evaluation. The
292
authors would also like to thank all the volunteers and healthcare professionals who dedicate their time
293
at popup clinics and other settings that use Ag-RDTs or NAATs. You are all instrumental for our
294
pandemic responses, and safety in our communities.
295
Author contributions
296
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
14. 14
JH, AB, NS, and JR identified this phenomenon, and were involved in food sample testing. JL, RD, GP, and
297
TH designed and undertook testing of water, buffer, media, and gargles. JL designed and performed the
298
buffer reverse engineering, conjugate pad transplantation, PK experiments and DSF experiments. MB,
299
AM, EM, BH, and PS designed and performed the temperature and humidity experiments. GP, JL, and TH
300
wrote the initial draft of the manuscript, with all authors contributing to the final version.
301
Transparency declaration
302
The authors declare that they have no conflicts of interest. This work received no private or public
303
funding, with the exception of the Panbio kits that were provided in-kind from the Public Health Agency
304
of Canada (PHAC).
305
Ethics
306
This evaluation was deemed exempt from Nova Scotia Health Research Ethics Board approval, as the
307
activities described in this manuscript were conducted in fulfillment of ongoing verification of SARS-CoV-
308
2 diagnostic assays used in Nova Scotia, and are therefore considered a quality assurance initiative.
309
Clinical specimens tested were obtained from anonymized residual samples collected for routine
310
diagnostic testing for SARS-CoV-2 from consenting participants, and all data related to clinical specimens
311
were provided anonymized, de-identified, and were used solely with the intent to evaluate the potential
312
for false positives in these clinical specimen types for rapid antigen testing programs used in Nova
313
Scotia.
314
References
315
1. Safiabadi Tali SH, LeBlanc JJ, Sadiq Z, Oyewunmi OD, Camargo C, Nikpour B, Armanfard N, Sagan SM,
316
Jahanshahi-Anbuhi S. 2021. Tools and techniques for severe acute respiratory syndrome coronavirus
317
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
15. 15
2 (SARS-CoV-2)/COVID-19 detection. Clin Microbiol Rev. 34(3):e00228-20. doi: 10.1128/CMR.00228-
318
20. PMID: 33980687.
319
2. Public Health Agency of Canada (PHAC). 2020. Interim guidance on the use of rapid antigen
320
detection tests for the identification of SARS-CoV-2 infection. https://www.canada.ca/en/public-
321
health/services/diseases/2019-novel-coronavirus-infection/guidance-documents/use-rapid-antigen-
322
detection-tests.html [last accessed September 9, 2021].
323
3. World Health Organization (WHO). 2020. Antigen-detection in the diagnosis of SARS-CoV-2 infection
324
using rapid immunoassays. Interim guidance. https://www.who.int/publications/i/item/antigen-
325
detection-in-the-diagnosis-of-sars-cov-2infection-using-rapid-immunoassays [last accessed
326
September 9, 2021].
327
4. US Food and Drug Administration. 2020. In vitro diagnostics EUAs. https://www.fda.gov/medical-
328
devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/vitro-
329
diagnostics-euas#individual-molecular [last accessed September 9, 2021].
330
5. Health Canada. 2020. Authorized medical devices for uses related to COVID-19: List of authorized
331
testing devices. https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-
332
industry/medical-devices/authorized/list.html [last accessed September 9, 2021].
333
6. Patriquin G, LeBlanc JJ. SARS-CoV-2 sensitivity limbo - How low can we go? Int J Infect Dis. 2021
334
Feb;103:23-24. doi: 10.1016/j.ijid.2020.11.138. Epub 2020 Nov 17. PMID: 33212261; PMCID:
335
PMC7669480.
336
7. Linares M, Pérez-Tanoira R, Carrero A, Romanyk J, Pérez-García F, Gómez-Herruz P, Arroyo T,
337
Cuadros J. 2020. Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7
338
days after the onset of symptoms. J Clin Virol. 133:104659. doi: 10.1016/j.jcv.2020.104659. Epub
339
2020 Oct 16. PMID: 33160179; PMCID: PMC7561603.
340
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
16. 16
8. Scheiblauer H, Filomena A, Nitsche A, Puyskens A, Corman VM, Drosten C, Zwirglmaier K, Lange C,
341
Emmerich P, Müller M, Knauer O, Nübling CM. 2021. Comparative sensitivity evaluation for 122
342
CE-marked SARS-CoV-2 antigen rapid tests. medRxiv 2021.05.11.21257016; doi:
343
https://doi.org/10.1101/2021.05.11.21257016
344
9. Gremmels H, Winkel BMF, Schuurman R, Rosingh A, Rigter NAM, Rodriguez O, Ubijaan J, Wensing
345
AMJ, Bonten MJM, Hofstra LM. 2021. Real-life validation of the Panbio COVID-19 antigen rapid test
346
(Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection.
347
EClinicalMedicine 31:100677. https://doi.org/10.1016/j.eclinm.2020.100677.
348
10. Merino P, Guinea J, Muñoz-Gallego I, González-Donapetry P, Galán JC, Antona N, Cilla G, Hernáez-
349
Crespo S, Díaz-de Tuesta JL, Gual-de Torrella A, González-Romo F, Escribano P, Sánchez-Castellano
350
MÁ, Sota-Busselo M, Delgado-Iribarren A, García J, Cantón R, Muñoz P, Folgueira MD, Cuenca-
351
Estrella M, Oteo-Iglesias J; Spanish Panbio™ COVID-19 validation group. 2021. Multicenter
352
evaluation of the Panbio COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2
353
infection. Clin Microbiol Infect. 27(5):758-61. doi: 10.1016/j.cmi.2021.02.001. Epub ahead of print.
354
PMID: 33601009; PMCID: PMC7884234.
355
11. Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes MÁ, Martínez M, Poujois S,
356
Forqué L, Valdivia A, Solano de la Asunción C, Ferrer J, Colomina J, Navarro D. 2021. Field evaluation
357
of a rapid antigen test (Panbio COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary
358
healthcare centres. Clin Microbiol Infect. 27(3):472.e7-472.e10. doi: 10.1016/j.cmi.2020.11.004.
359
Epub 2020 Nov 13. PMID: 33189872; PMCID: PMC7662075.
360
12. Stokes W, Berenger BM, Portnoy D, Scott B, Szelewicki J, Singh T, Venner AA, Turnbull L, Pabbaraju
361
K, Shokoples S, Wong AA, Gill K, Guttridge T, Proctor D, Hu J, Tipples G. 2021. Clinical performance of
362
the Abbott Panbio with nasopharyngeal, throat, and saliva swabs among symptomatic individuals
363
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
17. 17
with COVID-19. Eur J Clin Microbiol Infect Dis. 20:1-6. doi: 10.1007/s10096-021-04202-9. Epub
364
ahead of print. PMID: 33742322; PMCID: PMC7979467.
365
13. Food and Drug Administration (FDA). 2020. Potential for false positive results with antigen tests for
366
rapid detection of SARS-CoV-2 - Letter to clinical laboratory staff and health care providers.
367
https://www.fda.gov/medical-devices/letters-health-care-providers/potential-false-positive-results-
368
antigen-tests-rapid-detection-sars-cov-2-letter-clinical-laboratory (accessed June 21, 2021).
369
14. Nikolayevskyy V, Drobniewski F. 2020. False-positive COVID-19 results: hidden problems and costs.
370
Lancet Respir Med. 8(12):1167-1168. doi: 10.1016/S2213-2600(20)30453-7. Epub 2020 Sep 29.
371
PMID: 33007240; PMCID: PMC7524437.
372
15. The British Broadcasting Corporation (BBC). How children are spoofing Covid-19 tests with soft
373
drinks. July 5, 2021. https://www.bbc.com/future/article/20210705-how-children-are-spoofing-
374
covid-19-tests-with-soft-drinks. [last accessed September 9, 2021].
375
16. The Guardian. UK pupils use orange juice to fake ‘positive’ Covid test results. July 2, 2021.
376
https://www.theguardian.com/world/2021/jul/02/uk-pupils-orange-juice-fake-positive-covid-test-
377
results [last accessed September 9, 2021].
378
17. Newsweek. School kids using orange juice to get false positive COVID test results. June 6, 2021.
379
https://www.newsweek.com/school-kids-orange-juice-get-false-positive-covid-tests-
380
1604118?amp=1 [last accessed September 9, 2021].
381
18. iNews. Teenagers are figuring out how to fake positive Covid tests using lemon juice and hacks from
382
TikTok. July 1, 2021. https://inews.co.uk/news/technology/tiktok-fake-covid-positive-test-schools-
383
1079693 [last accessed September 9, 2021].
384
19. LeBlanc JJ, Heinstein C, MacDonald J, Pettipas J, Hatchette TF, Patriquin G. 2020. A combined
385
oropharyngeal/nares swab is a suitable alternative to nasopharyngeal swabs for the detection of
386
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
18. 18
SARS-CoV-2. J Clin Virol. 128:104442. doi: 10.1016/j.jcv.2020.104442. Epub 2020 May 16. PMID:
387
32540034; PMCID: PMC7228872.
388
20. Patriquin G, Davis I, Heinstein C, MacDonald J, Hatchette TF, LeBlanc JJ. 2020. Exploring alternative
389
swabs for use in SARS-CoV-2 detection from the oropharynx and anterior nares. J Virol Methods.
390
285:113948. doi: 10.1016/j.jviromet.2020.113948. Epub 2020 Aug 9. PMID: 32783913; PMCID:
391
PMC7415171.
392
21. LeBlanc JJ, Pettipas J, Di Quinzio M, Hatchette TF, Patriquin G. 2021. Reliable detection of SARS-CoV-
393
2 with patient-collected swabs and saline gargles: A three-headed comparison on multiple molecular
394
platforms. Journal of Virological Methods 295:114184. doi: 10.1016/j.jviromet.2021.114184. Epub
395
ahead of print. PMID: 34029634; PMCID: PMC8141269.
396
22. Davey L, Cohen A, LeBlanc J, Halperin SA, Lee SF. 2016. The disulfide oxidoreductase SdbA is active in
397
Streptococcus gordonii using a single C-terminal cysteine of the CXXC motif. Mol Microbiol.
398
99(2):236-53. doi: 10.1111/mmi.13227. Epub 2015 Oct 30. PMID: 26395460.
399
23. Gao K, Oerlemans R, Groves MR. 2020. Theory and applications of differential scanning fluorimetry
400
in early-stage drug discovery. Biophys Rev. 12(1):85-104. doi: 10.1007/s12551-020-00619-2. Epub
401
2020 Jan 31. PMID: 32006251; PMCID: PMC7040159.
402
24. Ramu T, Prasad ME, Connors E, Mishra A, Thomassin JL, LeBlanc JJ, Rainey JK, Thomas NA. 2013. A
403
novel C-terminal region within the multicargo type III secretion chaperone CesT contributes to
404
effector secretion. J Bacteriol. 195(4):740-56. doi: 10.1128/JB.01967-12. Epub 2012 Dec 7. PMID:
405
23222727; PMCID: PMC3562101.
406
25. Gillet P, Mori M, Van den Ende J, Jacobs J. 2010. Buffer substitution in malaria rapid diagnostic tests
407
causes false-positive results. Malar J. 9:215. doi: 10.1186/1475-2875-9-215. PMID: 20650003;
408
PMCID: PMC3224932.
409
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
19. 19
26. Wanji S, Amvongo-Adjia N, Njouendou AJ, Kengne-Ouafo JA, Ndongmo WP, Fombad FF, Koudou B,
410
Enyong PA, Bockarie M. 2016. Further evidence of the cross-reactivity of the Binax NOW Filariasis
411
ICT cards to non-Wuchereria bancrofti filariae: experimental studies with Loa loa and Onchocerca
412
ochengi. Parasit Vectors. 9:267. doi: 10.1186/s13071-016-1556-8. PMID: 27151313; PMCID:
413
PMC4858834.
414
27. Selby C. 1999. Interference in immunoassay. Ann Clin Biochem. 36(6):704-21. doi:
415
10.1177/000456329903600603. PMID: 10586307.
416
28. Haage V, Ferreira de Oliveira-Filho E, Moreira-Soto A, Kühne A, Fischer C, Sacks JA, Corman VM,
417
Müller MA, Drosten C, Drexler JF. 2021. Impaired performance of SARS-CoV-2 antigen-detecting
418
rapid diagnostic tests at elevated and low temperatures. J Clin Virol. 138:104796. doi:
419
10.1016/j.jcv.2021.104796. Epub 2021 Mar 16. PMID: 33773413; PMCID: PMC7962993.
420
29. Lin J, Dai W, Li W, Xiao L, Luo T, Guo Y, Yang Y, Han Y, Zhu P, Wu Q, He B, Wu J, Xia X. 2021. Potential
421
false-positive and false-negative results for COVID-19 IgG/IgM antibody testing after heat-
422
inactivation. Front Med (Lausanne). 7:589080. doi: 10.3389/fmed.2020.589080. PMID: 33537325;
423
PMCID: PMC7849051.
424
30. Siegler AJ, Hall E, Luisi N, Zlotorzynska M, Wilde G, Sanchez T, Bradley H, Sullivan PS. 2020.
425
Willingness to seek diagnostic testing for SARS-CoV-2 with home, drive-through, and clinic-based
426
specimen collection locations. Open Forum Infect Dis. 7(7):ofaa269. doi: 10.1093/ofid/ofaa269.
427
PMID: 32704517; PMCID: PMC7337815.
428
429
430
431
432
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
20. 20
Figure legends
433
Figure 1. Summary and principle of the Panbio COVID-19 Ag Rapid Test Device. A) Panbio kit
434
components and summary of the test procedure. The Panbio kit is designed for detection of SARS-CoV-2
435
antigen (i.e. nucleocapsid protein, or N protein). Following specimen collection, the swab is placed into
436
an extraction tube pre-filled with 11-12 drops, or 300 µl) of buffer, and the tube cap is added. The tube
437
is pinched to help extract the respiratory secretions from the swab, which in turn is rotated into the
438
buffer. The nozzle cap is removed from the extraction tube, and 5 drops are placed into the sample well
439
of the Panbio lateral flow device. After 15-20 minutes, the results are read and interpreted as depicted.
440
B) The principle of the Panbio Ag-RDT relies on a nitrocellulose membrane pre-coated with anti-chicken
441
IgY at the control line, and an anti-SARS-CoV-2 specific antibody at the test line. When the
442
buffer/specimen solution is added to the sample well, the liquid flows progressively through the device
443
using capillary action be sequentially flowing through the sample pad, the conjugate pad, the
444
nitrocellulose membrane, and eventually into the wick. As the liquid comes into contact with the
445
conjugate pad, both conjugated antibodies are resuspended (i.e. the gold-conjugated chicken IgY and
446
the gold-conjugated human IgG specific to SARS-CoV-2). In absence of SARS-CoV-2 antigen (i.e. N
447
protein), the conjugated anti-SARS-CoV-2 antibody will not interact with the anti-SARS-CoV-2 capture
448
antibody at the test line; however, the conjugated chicken IgY will be captured by the anti-chicken IgY
449
immobilized at the control line. This generates a red-colored band that can be visualized. In presence of
450
SARS-CoV-2 antigen, a similar reaction occurs at the test line due to the interaction between the antigen
451
and the conjugated and capture anti-SARS-CoV-2 antibodies. As seen in this study, false positives can
452
occur with testing conditions falling outside of the manufacturer instructions, depicted here as non-
453
specific interactions between the conjugated and capture anti-SARS-CoV-2 antibodies in absence of
454
antigen.
455
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
21. 21
Figure 2. False positives SARS-CoV-2 Ag-RDT results can occur from Panbio buffer absence, dilution, or
456
alterations. A) Artifact generation by Panbio buffer dilution in PCR-grade water at different
457
temperatures (4°C, 25°C, and 37°C). B) False positives SARS-CoV-2 Ag-RDT results occurrence from
458
uncontrolled pH and buffering conditions, or C) from changes in ionic strength from NaCl. All
459
experiments were performed in absence of SARS-CoV-2 antigen. False positive reactions are indicated as
460
POS (in red) under each Ag-RDT result.
461
Figure 3. Impact of proteinase K (PK) and heat treatment on the conjugated SARS-CoV-2 antibody. A)
462
Conjugate pad transplantation was used to access and investigate properties of the proprietary Panbio
463
conjugated antibodies. Each step was followed to as depicted leading to treatment of the conjugated
464
antibodies with proteinase K (PK) or heat (TC), and comparisons were made with untreated controls
465
(none). In some experiments (dashed arrows), the gold-conjugated antibody suspensions were pre-
466
treated with mouse anti-chicken IgY (obtained from a fragment of the nitrocellulose membrane at the
467
control line) to purify the gold-conjugated human IgG specific for SARS-CoV-2 conjugated antibody. This
468
suspension was used for subsequent lateral flow and thermal shift assays. B) PK and heat treatments of
469
the conjugated antibodies. Using conjugate pad transplantation, gold-conjugated antibody suspensions
470
in Panbio buffer or water were treated for an hour with PK at 56°C, followed by heat inactivation of PK
471
at 70°C for 10 min. Following re-introduction into Panbio cassettes of conjugated antibodies that were
472
untreated (none), heat-treated (TC), or PK-treated, and water was inoculated in the sample well. C)
473
Removal of the conjugated chicken IgY from the conjugated antibody suspensions, to purify the
474
conjugated SARS-CoV-2-specific antibody. Untreated (none) or pre-treatment (-IgY) are depicted for
475
reassembled Panbio cassettes containing the purified conjugated SARS-CoV-2-specific antibody, which
476
was then inoculated with PCR-grade water. For B) and C), similar reactions as performed for water were
477
undertaken with positive or negative control swab, to demonstrate the method did not impact
478
conjugate antibody function.
479
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
22. 22
Figure 4. Thermal shift profiles for the Panbio gold-conjugated human IgG specific to SARS-CoV-2 at
480
different pH values. All reactions were performed in 100 mM tricine, and representative thermal shift
481
profiles are presented in A). Melting temperatures (Tm) changes based on pH are summarized in B), as
482
well as a summary of which conditions were consistent (i.e. pH 5 to 7) or inconsistent (i.e. pH 8-10) with
483
generation of false positive results when tested by Ag-RDT.
484
485
486
487
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
23. 1
Table 1. Samples tested by SARS-CoV-2 Ag-RDTs with and without manufacturer buffer.
1
Category Brand Description
Avg.
pH (±
SD)
Panbio result Veritor result
RT-
PCR
result
Sample,
direct
Swab of
sample
in
buffer
Sample,
direct
Swab of
sample
in
buffer
Food
products
(n=33)
Bragg
Apple cider
vinegar
N/A INV NEG INV NEG N/A
N/A
Lemon, juice
(fresh)
N/A INV NEG INV NEG N/A
N/A
Lime, juice
(fresh)
N/A INV NEG INV NEG N/A
Nakano Rice vinegar N/A INV NEG NEG NEG N/A
Natrel
Milk, lactose-
free
N/A NEG NEG NEG NEG N/A
Scotsburn 18% Cream N/A NEG NEG NEG NEG N/A
Scotsburn Milk, 2% N/A NEG NEG NEG NEG N/A
Farmer's Milk, 2% N/A POS* NEG NEG NEG N/A
Farmer's Milk, 1% N/A POS* NEG NEG NEG N/A
Farmer's
Milk, fat-free
skim
N/A POS NEG NEG NEG N/A
Bubbly Soda N/A POS* NEG NEG NEG N/A
Pepsi Soda N/A POS* NEG NEG NEG N/A
Coca-Cola Soda N/A POS* NEG NEG NEG N/A
Tim Horton's
Apple juice,
pure
N/A POS* NEG NEG NEG N/A
Tim Horton's Coffee, black N/A POS NEG NEG NEG N/A
Simply
Apple juice,
pure pressed
N/A POS NEG NEG NEG N/A
N/A
Honeycrisp
apple, juice
(fresh)
N/A POS NEG NEG NEG N/A
N/A
Tangerine,
juice (fresh)
N/A POS NEG NEG NEG N/A
N/A
Watermelon,
juice (fresh)
N/A POS NEG NEG NEG N/A
N/A
Red grapes,
juice (fresh)
N/A POS NEG NEG NEG N/A
N/A
Green grapes,
juice (fresh)
N/A POS NEG NEG NEG N/A
N/A
Peach, juice
(fresh)
N/A POS NEG NEG NEG N/A
N/A
Wild
blueberries,
N/A POS NEG NEG NEG N/A
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
24. 2
juice (fresh)
N/A
Tomato, juice
(fresh)
N/A POS NEG NEG NEG N/A
N/A
English
cucumber,
juice (fresh)
N/A POS NEG NEG NEG N/A
Heinz Relish N/A POS NEG NEG NEG N/A
Heinz Ketchup N/A POS NEG NEG NEG N/A
Heinz Mustard N/A POS NEG NEG NEG N/A
Stellenbosch
Wine,
cabernet
N/A POS NEG NEG NEG N/A
Bud Light Beer N/A POS NEG NEG NEG N/A
Fisherman's
Helper
Rum, white N/A POS NEG NEG NEG N/A
Crown Royal
Maple
finished
whisky
N/A POS NEG NEG NEG N/A
Jameson Irish Whiskey N/A POS NEG NEG NEG N/A
Water
samples
(n=24)
Sigma Life
Sciences
Double
processed,
tissue culture
water, sterile
filtered
4.00
(±
0.01)
POS NEG NEG NEG NEG
Montellier
Carbonated
spring water
4.68
(±
0.00)
POS NEG NEG NEG NEG
Invitrogen
UltraPure
distilled
water, Dnase-
and Rnase-
free
4.80
(±
0.01)
POS NEG NEG NEG NEG
Aquafina
Demineralized
water, reverse
osmosis
5.05
(±
0.01)
POS NEG NEG NEG NEG
S. Pellegrino
Carbonated
natural
mineral water
5.09
(±
0.01)
POS NEG NEG NEG NEG
Canadian
Springs
Distilled
water,
osonized
5.31
(±
0.01)
POS NEG NEG NEG NEG
Dasani
Remineralized
water, reverse
osmosis
treated
5.68
(±
0.01)
POS NEG NEG NEG NEG
Big8
Distilled
water,
6.25
(±
POS NEG NEG NEG NEG
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
25. 3
ozonated 0.01)
Big8
Spring water,
ozonated
6.26
(±
0.01)
POS NEG NEG NEG NEG
Glaceau Smart
Vapour
distilled water
with added
electrolytes
6.71
(±
0.02)
POS NEG NEG NEG NEG
N/A
Municipal
water
(Halifax, Nova
Scotia,
May12, 2021)
6.75
(±
0.02)
POS NEG NEG NEG NEG
Fiji
Natural spring
water,
tropical rain
filtered
through
volcanic rock
7.25
(±
0.02)
POS NEG NEG NEG NEG
Simple Drop
Natural spring
water
7.26
(±
0.02)
POS NEG NEG NEG NEG
Pathwater
Purified
water, reverse
osmosis
treated,
ozonated, and
electrolytes
added, pH-
balanced, pH
7.5+
7.27
(±
0.01)
POS NEG NEG NEG NEG
Art Life WTR
Purified
water,
mineralized
and
electrolytes
added, pH-
balanced
7.28
(±
0.01)
POS NEG NEG NEG NEG
Evian
Spring water,
natural
electrolytes,
pH 7.2
7.39
(±
0.02)
POS NEG NEG NEG NEG
N/A
Rain water
(Halifax, Nova
Scotia, May
12, 2021)
7.47
(±
0.01)
POS NEG NEG NEG NEG
Icelandic Natural spring 7.58 POS NEG NEG NEG NEG
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
26. 4
Glacial water (±
0.02)
Nestle Pure
Life
Natural spring
water,
ozonated
7.75
(±
0.02)
POS NEG NEG NEG NEG
Earth Group Spring water
7.80
(±
0.03)
POS NEG NEG NEG NEG
Eska
Natural spring
water, pH 7.4
7.81
(±
0.00)
POS NEG NEG NEG NEG
#Smart
Moodwater
Naturally
alkaline spring
water, pH 8+
7.91
(±
0.01)
POS NEG NEG NEG NEG
Flow
Naturally
alkaline spring
water, pH 8.1
8.02
(±
0.00)
POS NEG NEG NEG NEG
Glaceau Smart
Mineralized
treated water,
alkaline pH 9+
9.33
(±
0.00)
POS NEG NEG NEG NEG
Laboratory
buffers
and media
(n=14)
Teligent 0.9% Saline
5.62
(±
0.02)
POS
(weak)
NEG NEG NEG NEG
Boston
BioProducts
0.5M Pipes
buffer, pH 6.8
6.66
(±
0.01)
POS* NEG NEG NEG NEG
FisherScientific
10 mM Tris-
HCl; 1 mM
EDTA (TE)
buffer,
molecular-
grade pH 7.4
7.14
(±
0.01)
POS NEG NEG NEG NEG
Sigma Life
Sciences
Dulbecco's
Phosphate
Buffered
Saline (PBS)
7.18
(±
0.01)
POS* NEG NEG NEG NEG
LiofilChem
Viral
Transport
Media (VTM)
7.24
(±
0.01)
POS* NEG NEG NEG NEG
Redoxica
Viral
Transport
Media (VTM)
with fetal
bovine serum
(FBS)
7.33
(±
0.01)
POS* NEG NEG NEG NEG
Becton
Dickinson
Veritor
sample buffer
7.33
(±
NEG NEG NEG NEG NEG
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
27. 5
0.00)
Copan
Diagnostics
Universal
Transport
Medium
(UTM)
7.37
(±
0.01)
NEG NEG NEG NEG NEG
Yokon
Universal
Transport
Medium
(UTM)
7.44
(±
0.01)
NEG NEG NEG NEG NEG
Gibco
RPMI medium
1640, with
HEPES
7.48
(±
0.01)
NEG NEG NEG NEG NEG
Genesis
KaiBiLi
Extended
ViralTrans,
includes
HEPES
7.50
(±
0.01)
NEG NEG NEG NEG NEG
Gibco
Minimal
Essential
Media (MEM)
7.83
(±
0.01)
NEG NEG NEG NEG NEG
Gibco
1x Phosphate
Buffered
Saline (PBS),
pH 7.4
8.20
(±
0.01)
NEG NEG NEG NEG NEG
Abbott
Panbio
sample buffer
8.78
(±
0.01)
NEG NEG NEG NEG NEG
Clinical
specimens
(n=120)
N/A
NP swabs in
UTM (n=30)
N/A
POS*
(28/30)
NEG NEG NEG NEG
N/A
OP/N swabs
in PBS (n=30)
N/A
POS*
(26/30)
NEG NEG NEG NEG
N/A BALs (n=30) N/A
POS*
(27/30)
NEG NEG NEG NEG
N/A
Saline gargles
(n=30)
N/A
POS*
(27/30)
NEG NEG NEG NEG
*Only weak positive reactions were observed.
2
All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
28. All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
29. All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
30. All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint
31. All rights reserved. No reuse allowed without permission.
preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this
this version posted September 16, 2021.
;
https://doi.org/10.1101/2021.07.04.21259490
doi:
medRxiv preprint